Understanding Why Sponsors are ‘Re-Thinking’ DCT Adoption
September 1, 2023
In this guest column, Ken Getz, Professor and Executive Director, Tufts Center for the Study of Drug Development, presents data-driven insights into why adoption of decentralized trial (DCT) methods is lagging.